Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

• Status: Active, not recruiting
• Trial end date: 2021-12-01

Summary

This phase Ib/II trial studies the side effects and best dose of bispecific antibody armed activated T-cells when given together with aldesleukin and sargramostim and to see how well they work in treating patients with pancreatic cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic). Bispecific antibody armed activated T-cells are the patient's own T cells that are coated with a bispecific antibody comprising 2 antibodies chemically joined together. These antibodies have specific targets and binding properties that may give the T cells a greater ability to seek out, attach to, and kill more cancer cells.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Barbara Ann Karmanos Cancer Institute
• Collaborator: National Cancer Institute (NCI)
• Treatments: Albumin-Bound Paclitaxel; Aldesleukin; Antibodies; Antibodies, Bispecific; Calcium; Calcium, Dietary; Camptothecin; Fluorouracil; Folic Acid; Gemcitabine; Immunoglobulins; Interleukin-2; Irinotecan; Leucovorin; Levoleucovorin; Oxaliplatin; Paclitaxel; Sargramostim